Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Rating of “Moderate Buy” from Analysts

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has earned an average recommendation of “Moderate Buy” from the twenty-seven ratings firms that are currently covering the stock, MarketBeat reports. Nine analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $787.8750.

A number of research analysts have commented on REGN shares. JPMorgan Chase & Co. decreased their price target on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a research note on Monday, May 18th. Wells Fargo & Company reduced their target price on shares of Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating on the stock in a report on Monday, May 18th. Canaccord Genuity Group cut their price objective on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. HSBC cut their price objective on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. Finally, Morgan Stanley decreased their target price on Regeneron Pharmaceuticals from $788.00 to $730.00 and set an “equal weight” rating for the company in a report on Wednesday, July 8th.

Insider Activity

In other news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the transaction, the director directly owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in REGN. Brighton Jones LLC raised its stake in Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after acquiring an additional 686 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $226,000. Arrowstreet Capital Limited Partnership acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $3,183,000. Gabelli Funds LLC raised its stake in shares of Regeneron Pharmaceuticals by 3.0% during the second quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company’s stock worth $978,000 after purchasing an additional 55 shares during the last quarter. Finally, Sei Investments Co. raised its stake in shares of Regeneron Pharmaceuticals by 18.8% during the second quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company’s stock worth $16,985,000 after purchasing an additional 5,120 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Several articles say Regeneron is expected to beat second-quarter earnings estimates, which could reinforce confidence ahead of the company’s upcoming report. Analysts cited stronger-than-expected fundamentals as a reason for optimism. Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
• Positive Sentiment: Guggenheim reportedly raised its price target on Regeneron to $1,000, a sign that at least one Wall Street firm remains very constructive on the company’s long-term prospects. Guggenheim Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,000.00
• Neutral Sentiment: More pre-earnings coverage suggests analysts expect earnings to decline year over year, so the upcoming report will need to show strong execution to keep sentiment positive. Here’s What to Expect From Regeneron Pharmaceuticals’ Next Earnings Report
• Negative Sentiment: A wave of class-action lawsuit alerts and deadline reminders is weighing on sentiment, with allegations tied to disclosures around a Phase III Fianlimab-Libtayo melanoma trial and claims that risks were understated. SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit – REGN
• Negative Sentiment: Multiple law firms are urging investors to join securities fraud litigation, highlighting the earlier sharp share-price drop after the failed Phase 3 trial announcement and keeping legal overhang front and center. REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit – Investors With Losses May Contact Levi & Korsinsky

Regeneron Pharmaceuticals Trading Up 0.1%

Shares of Regeneron Pharmaceuticals stock opened at $651.91 on Friday. The company has a market capitalization of $68.92 billion, a P/E ratio of 15.88, a P/E/G ratio of 1.44 and a beta of 0.24. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. The company has a fifty day moving average of $636.62 and a 200 day moving average of $714.85. Regeneron Pharmaceuticals has a fifty-two week low of $541.00 and a fifty-two week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. The business had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company’s revenue was up 19.0% on a year-over-year basis. During the same quarter last year, the business posted $8.22 EPS. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 37.12 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were given a $0.94 dividend. The ex-dividend date of this dividend was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.16%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.